EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Frequently asked questions
What sector does Eyepoint Pharmaceuticals Inc (EYPT) operate in?
Eyepoint Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Eyepoint Pharmaceuticals Inc (EYPT) current stock price?
As of the latest data, Eyepoint Pharmaceuticals Inc stock price is $4.87, with a previous close of $14.75. Eyepoint Pharmaceuticals Inc lost -$9.88 in the last trading session, representing a -66.98% loss.
What is Eyepoint Pharmaceuticals Inc (EYPT) current market capitalization?
Eyepoint Pharmaceuticals Inc market cap is approximately 419.85 million.
What is Eyepoint Pharmaceuticals Inc (EYPT) Earnings Per Share (EPS)?
The trailing EPS is -$3.75, and the forward EPS is -$3.08.
What is Eyepoint Pharmaceuticals Inc (EYPT) EBITDA?
Eyepoint Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -93.14 million.
Does Eyepoint Pharmaceuticals Inc (EYPT) pay dividends?
No. Eyepoint Pharmaceuticals Inc does not pay a dividend.
How did Eyepoint Pharmaceuticals Inc (EYPT) perform in its most recent earnings report?
In the last report (June 30, 2026), Eyepoint Pharmaceuticals Inc posted an EPS surprise of -18.48% and a revenue surprise of 36.18%.
What is Eyepoint Pharmaceuticals Inc (EYPT) beta (volatility) score?
Eyepoint Pharmaceuticals Inc has a beta of 1.739, suggesting it is more volatile than the market.
